[794] Assessment of TMPRSS2: ERG (T:E) Gene Fusion in Prostatic Adenocarcinoma (CaP) by Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry(IHC): Correlation of ERG Break-Apart and T:E Fusion Probes with ERG and TMPRSS2 Protein Expression
Melissa Bastacky, Marissa Gogniat, Carol Sherer, Kathleen Cieply, Aron Gedansky, Sheri Kavala, Anil Parwani, Rajiv Dhir, Marie Acquafondata, Franto Francis, Sheldon Bastacky. University of Pittsburgh, Pittsburgh, PA
Background: T:E gene fusion leading to transcription factor ERG protein overexpression occurs in many CaPs. T:E gene fusion can be assessed using ERG break-apart and T:E fusion probes. The aim of this study is to compare both probe methods, correlating results with ERG and TMPRSS2 protein expression.
Design: Formalin-fixed, paraffin-embedded tissue sections from 21 CaP pt samples (tissue microarray (n=10), needle bx (n=3), radical prostatectomy (n=8)) and control organ donor prostates (ODP; n=10) were obtained from the University of Pittsburgh tissue bank. Dual-color FISH (break-apart probe for ERG disruption, separate ERG and TMPRSS2 probes for T:E fusion) and immunohistochemistry (ERG (Biocare Medical) and TMPRSS2 (Epitomics)) were performed. FISH was positive if ≥ 20% of cells had ERG disruption or T:E fusion, with thresholds based on ODPs. IHC intensity (0-3) and distribution (0-100%) were scored. FISH and IHC results were correlated.
Results:
| Gleason score | *ERG (FISH) | *T:E (FISH) | *ERG (IHC) | **TMPRSS2 (IHC) |
| 3+3=6 | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) | 4/4 (100%) |
| 3+4=7 | 4/7 (57%) | 5/7 (71%) | 4/7 (51%) | 7/7 (100%) |
| 4+3=7 | 3/5 (60%) | 3/5 (60%) | 2/5 (40%) | 5/5 (100%) |
| 4+4=8 | 2/5 (40%) | 3/5 (60%) | 2/5 (40%) | 5/5 (100%) |
| FISH+/Total | ERG-IHC+/FISH+ | ERG (mean intensity score of + cases) | |
| ERG- break-apart (total) | 15/21 (71%) | 12/15 (80%) | 2.1/3 |
| - ERG-BT | 9/21 (43%) | 9/9 (100%) | 3/3 |
| - ERG-UBT | 4/21 (19%) | 2/4 (50%) | 1/3 |
| - ERG-BT+UBT | 2/21 (9%) | 1/2 (50%) | 3/3 |
| T:E fusion | 15/21 (71%) | 12/15 (80%) | 2.1/3 |